Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Director | September 07, 2017 | September 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date September 07, 2017 · Filed September 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-09-06 | Direct | 10,900 |
Reported balance
After 2017-09-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-07 · Grant · Acquired 10,900 · Balance 10,900 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2017 Filed Sep 12, 2017 00:20 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 10,900 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-052311 · doc4.xml · derivative · entry 1 DRAPEAU LOUIS · CIK 0001248091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,900 Underlying: Common Stock · 10,900 shares Expires 2027-09-06 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.